PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
29341316-0	2018	Deferoxamine promotes mesenchymal stem cell homing in noise-induced injured cochlea through PI3K/AKT pathway.	Deferoxamine	0-12	AKT serine/threonine kinase 1	Rattus norvegicus	97-100	
11294857-5	2001	The hypoxia-dependent protection from apoptosis correlates with activation of the phosphatidylinositol 3-kinase (PI3K)/Akt pathway, which is detected after 3-4 h of hypoxic or deferoxamine treatment and is sustained while hypoxic conditions are maintained.	Deferoxamine	176-188	AKT serine/threonine kinase 1	Rattus norvegicus	119-122	
18245813-6	2008	Deferoxamine consistently increased the phosphorylation status of Akt/PKB and its targets FoxO1 and Gsk3beta, which mediate the effect of insulin on gluconeogenesis and glycogen synthesis, and up-regulated genes involved in glucose uptake and utilization.	Deferoxamine	0-12	AKT serine/threonine kinase 1	Rattus norvegicus	66-73	
32729002-11	2020	Expression of cleaved caspase 3 and pAKT/AKT ratio obviously demonstrated DFO can resist the cells against cytotoxicity.	Deferoxamine	74-77	AKT serine/threonine kinase 1	Rattus norvegicus	37-40	
29341316-3	2018	Deferoxamine (DFO) can induce the Akt activation, and phosphorylation status of AKT (p-AKT) upregulates CXC chemokine receptor-4 (CXCR4) expression.	Deferoxamine	0-12	AKT serine/threonine kinase 1	Rattus norvegicus	34-37	
29341316-3	2018	Deferoxamine (DFO) can induce the Akt activation, and phosphorylation status of AKT (p-AKT) upregulates CXC chemokine receptor-4 (CXCR4) expression.	Deferoxamine	0-12	AKT serine/threonine kinase 1	Rattus norvegicus	80-83	
29341316-3	2018	Deferoxamine (DFO) can induce the Akt activation, and phosphorylation status of AKT (p-AKT) upregulates CXC chemokine receptor-4 (CXCR4) expression.	Deferoxamine	0-12	AKT serine/threonine kinase 1	Rattus norvegicus	85-90	
29341316-3	2018	Deferoxamine (DFO) can induce the Akt activation, and phosphorylation status of AKT (p-AKT) upregulates CXC chemokine receptor-4 (CXCR4) expression.	Deferoxamine	14-17	AKT serine/threonine kinase 1	Rattus norvegicus	34-37	
29341316-3	2018	Deferoxamine (DFO) can induce the Akt activation, and phosphorylation status of AKT (p-AKT) upregulates CXC chemokine receptor-4 (CXCR4) expression.	Deferoxamine	14-17	AKT serine/threonine kinase 1	Rattus norvegicus	80-83	
29341316-3	2018	Deferoxamine (DFO) can induce the Akt activation, and phosphorylation status of AKT (p-AKT) upregulates CXC chemokine receptor-4 (CXCR4) expression.	Deferoxamine	14-17	AKT serine/threonine kinase 1	Rattus norvegicus	85-90	
29341316-4	2018	We examined whether DFO can enhance mesenchymal stem cells (MSCs) homing in noise-induced damaged cochlea by PI3K/AKT dependent mechanism.	Deferoxamine	20-23	AKT serine/threonine kinase 1	Rattus norvegicus	114-117	
29341316-10	2018	RESULTS: Deferoxamine increased P-AKT, HIF-1alpha and CXCR4 expression in MSCs compared to non-treated cells.	Deferoxamine	9-21	AKT serine/threonine kinase 1	Rattus norvegicus	34-37	
29341316-13	2018	CONCLUSIONS: Pre-conditioning of MSCs by DFO before transplantation can improve stem cell homing in the damaged cochlea through PI3K/AKT pathway activation.	Deferoxamine	41-44	AKT serine/threonine kinase 1	Rattus norvegicus	133-136	
25075254-8	2014	However, the expression of p-Akt was unchanged in DFO treated group compared with control group.	Deferoxamine	50-53	AKT serine/threonine kinase 1	Rattus norvegicus	29-32